176 results on '"Scalone, Simona"'
Search Results
2. Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)
3. Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21)
4. Trabectedin may be a valuable treatment option for elderly patients with metastatic soft tissue sarcomas.
5. A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer
6. Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials
7. Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas
8. Metabolic Clues to Bile Acid Patterns and Prolonged Survival in Patients with Metastatic Soft-Tissue Sarcoma Treated with Trabectedin
9. Pharmacometabolomics of trabectedin in metastatic soft tissue sarcoma patients
10. Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget’s disease of the vulva
11. Abstract P4-02-06: Clinical and biological predictors of lymph node involvement in patients with early breast cancer for adjuvant treatment personalization
12. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial
13. TP003/#1533 MITO CERV3_phase II study on carboplatin-paclitaxel-pembrolizumab in neoadjuvant treatment of locally advanced cervical cancer
14. Evidence-Based Medicine: What does it Mean and Where Are We Going?
15. An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
16. Breast cancer incidence in patients with BRCA-related advanced ovarian cancer receiving olaparib-based maintenance therapy: A pooled analysis from phase III clinical trials.
17. KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer
18. MITO END-3: A Randomized Phase II Trial of Avelumab Plus Carboplatin and Paclitaxel Compared to Carboplatin and Paclitaxel in Advanced or Recurrent Endometrial Cancer
19. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines
20. Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?
21. A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial
22. Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer
23. Integration of Serum Metabolomics into Clinical Assessment to Improve Outcome Prediction of Metastatic Soft Tissue Sarcoma Patients Treated with Trabectedin
24. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
25. Treatment of early stage breast cancer in the elderly
26. Vinorelbine-induced Acute Reversible Peripheral Neuropathy in a Patient with Ovarian Carcinoma Pretreated with Carboplatin and Paclitaxel
27. Staphylococcus cohnii septicaemia in a patient with colon cancer
28. Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)
29. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach
30. Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC)? A network meta-analysis (NMA).
31. Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised study
32. Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers
33. Angiogenesis and Tumor Growth
34. Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)
35. Primary extragenital endometrial stromal sarcoma of the lung: first reported case and review of literature
36. Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer
37. Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis
38. Clinical validity of aDPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines
39. Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients
40. Second-Line Chemotherapy in Recurrent Clear Cell Ovarian Cancer: Results from the Multicenter Italian Trials in Ovarian Cancer (MITO-9)
41. Bevacizumab as maintenance therapy (mBev) in metastatic breast cancer (MBC).
42. Paraneoplastic cerebellar degeneration associated with ovarian cancer
43. A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies
44. Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?
45. Therapeutic management of breast cancer in the elderly
46. Multicenter Phase 2 Study of Combined Gemcitabine and Epirubicin as Second-Line Treatment for Patients With Advanced Ovarian Cancer
47. Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised study
48. Epirubicin and Docetaxel as Neoadjuvant Treatment of Locally Advanced Breast Cancer: A Phase II Study
49. Hormone therapy in elderly breast cancer patients with comorbidities
50. Incidence of Palmar-Plantar Erythrodysesthesia in Pretreated and Unpretreated Patients Receiving Pegylated Liposomal Doxorubicin
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.